Bridgewater-based Cosette Pharmaceuticals on Friday announced it completed its acquisition of Intrarosa from Endoceutics, a subsidiary of Endorecherche Inc. The transaction includes 108 issued and pending patents across the globe with the latest expiring in 2033, including three Orange Book listed patents.
“This transformative acquisition further strengthens Cosette’s commitment to women’s health with a patent protected, novel drug formulation. In partnership with MSH Pharma Inc., Cosette will leverage its unique commercial and manufacturing capabilities to ensure continued patient access to Intrarosa. We look forward to expanding Cosette’s global footprint in new territories and with our existing distribution partners,” Apurva Saraf, CEO and president of Cosette, stated.
Intrarosa is the only prescription drug providing both estrogen and androgen for the treatment of moderate-to-severe dyspareunia (a common symptom of vulvar and vaginal atrophy due to menopause). Unlike conventional pharmacological estrogen-containing medications, the unique label of Intrarosa differentiates it from all other hormone replacement therapies on the market today, in that it does not carry a boxed safety warning on its label.